SYRE at a glance
The past year
Chart+316.5% $101.46, close Nov 18
- From the highest close
- −6.9%
- Vs the 200-day average
- +30.7%
Short interest
History11.6M shares
- Of shares outstanding
- 12.2%
- Since the last report
- −7.1%
- Days to cover
- 13 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 12 – Nov 18
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
SYRE price history
Loading recent earnings…
Investment thesis
What must happen next
Spyre’s long-acting antibody and antibody-combination design must prove a clinically meaningful convenience-plus-outcomes advantage in IBD and rheumatic diseases; otherwise the company has no commercial engine to convert into sales.HoldingMateriality: High
Company description identifies Spyre as a clinical-stage biotechnology company focused on long-acting antibodies and antibody combinations for inflammatory bowel disease and rheumatic diseases. If the differentiation is real, zero-revenue clinical assets can re-rate sharply; if not, the business remains an expensive R&D program with little pricing power.
Watch: Approved biologics or oral therapies in IBD and rheumatic disease show efficacy, safety, or dosing profiles that leave little room for Spyre to differentiate.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Company description identifies Spyre as a clinical-stage biotechnology company focused on long-acting antibodies and antibody combinations for inflammatory bowel disease.
Open source ↗Because Spyre is pre-commercial, the balance sheet must fund clinical catalysts without forcing a weak financing before value-inflecting data arrive.HoldingMateriality: High
Cash and cash equivalents were $85.721 million at FY2025 year-end on a GAAP balance-sheet basis. Adequate runway lets owners participate in clinical upside; inadequate runway shifts value to new investors through dilution or unfavorable deal terms.
Watch: Clinical trial scope expands materially, raising burn before the next meaningful data readout.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash and cash equivalents were $85.721 million at FY2025 year-end on a GAAP balance-sheet basis.
Open source ↗A focused organization must be able to execute the Phase 2 platform efficiently; if Spyre needs a much larger fixed-cost base before proving the science, operating leverage for shareholders deteriorates.StrengtheningMateriality: Medium
Spyre had 102 full-time employees as of December 31, 2025. Efficient execution preserves option value per dollar of capital; execution bloat turns clinical uncertainty into capital-allocation risk.
Watch: Enrollment problems force prolonged site expansion or major CRO remediation.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Spyre had 102 full-time employees as of December 31, 2025.
Open source ↗The cash burn must keep buying decision-quality clinical evidence rather than merely extending a no-revenue research cycle.HoldingMateriality: Medium
GAAP annual operating cash flow was negative $169.252 million in FY2025 versus negative $157.410 million in FY2024, showing substantial ongoing development spending. Owners benefit if each year of losses increases probability-weighted asset value; they lose if losses compound without clearer clinical or regulatory paths.
Watch: Phase 2 data are delayed, inconclusive, or require repeated redesigns without narrowing the development path.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was negative $169.252 million in FY2025 versus negative $157.410 million in FY2024, showing substantial ongoing.
Open source ↗Shareholder value depends on raising and deploying capital after scientific de-risking rather than repeatedly funding losses ahead of proof.HoldingMateriality: Medium
Stockholders’ equity rose to $715.236 million at FY2025 year-end from $517.804 million at FY2024 year-end and $184.016 million at FY2023 year-end. Even successful science can be a poor stock if ownership is diluted too heavily before the value inflection.
Watch: A discounted equity raise occurs before differentiated Phase 2 data.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Stockholders’ equity rose to $715.236 million at FY2025 year-end from $517.804 million at FY2024 year-end and $184.016 million at FY2023.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Spyre’s long-acting antibody and antibody-combination design must prove a clinically meaningful convenience-plus-outcomes advantage in IBD and rheumatic diseases; otherwise the company has no commercial engine to convert into sales. If the differentiation is real, zero-revenue clinical assets can re-rate sharply; if not, the business remains an expensive R&D program with little pricing power.
Because Spyre is pre-commercial, the balance sheet must fund clinical catalysts without forcing a weak financing before value-inflecting data arrive. Adequate runway lets owners participate in clinical upside; inadequate runway shifts value to new investors through dilution or unfavorable deal terms.
A focused organization must be able to execute the Phase 2 platform efficiently; if Spyre needs a much larger fixed-cost base before proving the science, operating leverage for shareholders deteriorates. Efficient execution preserves option value per dollar of capital; execution bloat turns clinical uncertainty into capital-allocation risk.
The cash burn must keep buying decision-quality clinical evidence rather than merely extending a no-revenue research cycle. Owners benefit if each year of losses increases probability-weighted asset value; they lose if losses compound without clearer clinical or regulatory paths.
Shareholder value depends on raising and deploying capital after scientific de-risking rather than repeatedly funding losses ahead of proof. Even successful science can be a poor stock if ownership is diluted too heavily before the value inflection.
All standing thesis claims
Original report summary
Spyre is a high-risk clinical-stage option on long-acting antibody and antibody-combination drugs becoming differentiated treatments in IBD and rheumatic diseases before the company has to finance too much more burn.
Bull case and bear case
Bull case and bear case for Spyre Therapeutics
Where the evidence on Spyre Therapeutics stands: Holding on the latest evidence (Oct 14, 2026). Of its 5 thesis points, 1 strengthening and 4 holding.
Bull case: what the evidence supports
Spyre’s long-acting antibody and antibody-combination design must prove a clinically meaningful convenience-plus-outcomes advantage in IBD and rheumatic diseases; otherwise the company has no commercial engine to convert into sales.
Because Spyre is pre-commercial, the balance sheet must fund clinical catalysts without forcing a weak financing before value-inflecting data arrive.
A focused organization must be able to execute the Phase 2 platform efficiently; if Spyre needs a much larger fixed-cost base before proving the science, operating leverage for shareholders deteriorates.
The cash burn must keep buying decision-quality clinical evidence rather than merely extending a no-revenue research cycle.
Shareholder value depends on raising and deploying capital after scientific de-risking rather than repeatedly funding losses ahead of proof.
Bear case: what would count against it
Approved biologics or oral therapies in IBD and rheumatic disease show efficacy, safety, or dosing profiles that leave little room for Spyre to differentiate.
Clinical trial scope expands materially, raising burn before the next meaningful data readout.
Enrollment problems force prolonged site expansion or major CRO remediation.
Thesis-Break Engine
What has broken in Spyre Therapeutics’s thesis
Each break OptimistFi flagged on Spyre Therapeutics, dated — with what has historically followed the same kind of break across the market, not a forecast for Spyre Therapeutics.
- Insider-selling clustercondition set before this filing
Across all companies, this kind of break has happened 9,137 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 30% of them trailed it by 10 points or more.
Early warning
The break condition read on the trailing twelve months through Spyre Therapeutics’s latest quarterly report, ahead of the annual figure it is written on.
- Net loss, trailing 12 months
Across all companies, this kind of early warning has happened 2,059 times before. Those stocks beat comparable companies by a median of 1% over the next six months, and 35% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedEntered a material definitive agreement.
Spyre Therapeutics filed an SEC 8-K on 2026-10-07: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Spyre Therapeutics filed an SEC 8-K on 2026-09-08: Regulation FD disclosure. It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Spyre Therapeutics filed an SEC 8-K on 2026-08-25: Regulation FD disclosure. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Approved biologics or oral therapies in IBD and rheumatic disease show efficacy, safety, or dosing profiles that leave little room for Spyre to differentiate.
- Clinical trial scope expands materially, raising burn before the next meaningful data readout.
- Enrollment problems force prolonged site expansion or major CRO remediation.
- Phase 2 data are delayed, inconclusive, or require repeated redesigns without narrowing the development path.
- A discounted equity raise occurs before differentiated Phase 2 data.
SYRE news
Loading headlines…
Financial statements
SYRE income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
SYRE: quick answers
- When does Spyre Therapeutics (SYRE) report earnings next?
- Spyre Therapeutics's next results are projected for February 18, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 3, 2026. Earnings calendar
- What is SYRE's short interest?
- As of October 30, 2026, 11.6M SYRE shares were sold short, 12.2% of its shares outstanding, down 7.1% from the count before. At the stock's average daily volume that is 13 days to cover. FINRA publishes the count twice a month. SYRE short interest history

